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Renal hemodynamic effects of L-arginine and sodium nitro- rate (GFR) and renal plasma flow (RPF) [2, 3]. Because
prusside in heart transplant recipients. of the lack of histological lesions, the acute toxicity is
Background. Long-term treatment with cyclosporine A believed to be a consequence of preglomerular vasocon-(CsA) induces vasoconstriction in the kidney and causes renal
striction [4]. After prolonged CsA administration, chronicimpairment. An altered l-arginine (L-Arg)/nitric oxide (NO)
nephrotoxicity is characterized by a progressive and irre-pathway may play a key role in CsA nephrotoxicity.
Methods. We studied the effect of L-Arg (dosage, 17 mg/ versible impairment of renal function [5–7]. Approxi-
kg/min over 30 min), the precursor of NO synthesis, and sodium mately 5% of cardiac transplant recipients develop end-
nitroprusside (SNP; dosage, 1.0 mg/kg/min over 30 min) on stage renal disease requiring hemodialysis or subsequentrenal hemodynamics in a double-blind, placebo-controlled,
renal transplantation five years after heart transplanta-randomized, three-way cross-over study comprising 12 stable
tion [8]. It has been shown that the acute nephrotoxicitycardiac transplant recipients on long-term CsA treatment, 10
patients with chronic nephropathy not receiving CsA, and 13 of CsA is completely reversible after dose reduction or
healthy controls. Renal plasma flow (RPF) and glomerular drug withdrawal [9]. In heart transplant recipients, how-
filtration rate (GFR) were measured by paraaminohippurate ever, a weaning of CsA may be associated with severe(PAH) and the inulin clearance method, respectively.
rejection and subsequent graft failure. Hence, until now,Results. In healthy subjects, L-Arg induced an increase in
there is no adequate substitute for CsA, resulting in aRPF (P 5 0.009) and GFR (P 5 0.001). By contrast, L-Arg
did not induce renal hemodynamic effects in heart transplant clinical need to improve renal tolerability of CsA.
patients or patients with chronic nephropathy. SNP reduced Experimental evidence suggests an imbalance of vaso-
RPF (P 5 0.050) and GFR (P 5 0.005) in patients with chronic active substances in the pathogenesis of renal vasocon-nephropathy but did not affect renal hemodynamics in heart
striction initiating CsA nephrotoxicity. Among thesetransplant recipients or in healthy subjects.
agents, nitric oxide (NO) may play a key role [10–12].Conclusions. These data indicate that L-Arg cannot be used
to reverse CsA-induced renal vasoconstriction in heart trans- Although renal vasoconstriction associated with CsA is
plant recipients under long-term CsA treatment, although not directly mediated by NO deficiency [13], it has been
these patients have a normal renal response to SNP. shown that l-arginine (L-Arg), the precursor of NO syn-
thesis, protects against cyclosporine nephrotoxicity in
animal models [10, 12]. Based on these data, we hypothe-
Cyclosporine A (CsA) is a potent immunosuppressive sized that L-Arg administration may increase renal blood
agent that is widely used in transplantation to prevent flow in heart transplant recipients.
allograft rejection [1]. Although effective to prevent graft
rejection, CsA administration can cause acute renal fail-
METHODSure, which occurs soon after transplantation with oligu-
ria, and acute impairment of the glomerular filtration Subjects
After approval from the Ethics Committee of Vienna
University School of Medicine was obtained, 12 cardiacKey words: cyclosporine, renal plasma flow, nitric oxide, glomerular
filtration rate, transplantation. transplant recipients, 10 patients with chronic nephropa-
thy, and 13 healthy, age-matched controls were studied.Received for publication June 11, 1998
The nature of the study was explained, and all subjectsand in revised form September 11, 1998
Accepted for publication December 16, 1998 gave written consent to participate. Each subject passed
a screening examination that included medical history 1999 by the International Society of Nephrology
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Table 1. Study population ied in order to investigate whether an abnormal response
to L-Arg in HTX patients could generally be attributedHTX Nephropathy Controls
to altered renal function or specifically to cyclosporine-Age years 60.269.4 64.2 69.3 59.468.5
Time after HTX months 55.8621.2 — — induced nephrotoxicity. The underlying disease was sys-
CsA mean dose/day mg 222682 — — temic hypertension in eight patients and glomerulone-
CsA plasma levels ng/ml 161656 — —
phritis in two patients. Inclusion criteria were systemicBUN mg/dl 30.268.4 38.9 615.6 17.464.8
Creatinine clearance ml/min 60.569.1 52.7 613.8 112.6615.8 hypertension [defined as a systolic blood pressure (SBP)
of more than 150 mm Hg or diastolic blood pressureCharacteristics of heart transplant recipients (HTX; N 5 12), patients with
chronic nephropathy (Nephropathy; N 5 10), and healthy control subjects (Con- (DBP) of more than 85 mm Hg] and a creatinine clear-
trols; N 5 13) are shown.
ance between 30 and 70 ml/min. None of the patientsData are presented as means 6 sd.
were on CsA treatment. Concomitant antihypertensive
treatment was adapted according to cardiac transplant
recipients.
and physical examination, 12-lead electrocardiogram, Healthy control subjects. This study group consisted
complete blood count, activated partial thromboplastin of 13 healthy, male, age-matched volunteers with normal
time, thrombin time, fibrinogen, clinical chemistry (so- renal function. Subjects were excluded if any abnormal-
dium, potassium, creatinine, blood urea nitrogen, uric ity was found as part of the prescreening procedure.
acid, glucose, cholesterol, triglycerides, alanine amino-
Study designtransferase, aspartate transcarbamylase, g-glutamyltrans-
ferase, alkaline phosphatase, total bilirubin, and total All subjects were studied in a randomized, double-
protein), hepatitis A, B, and C and HIV serology, urine blind, placebo-controlled, three-way cross-over design,
analysis, and 24-hour urine collection to determine creat- with washout periods of at least two days. The random-
inine clearance. In addition, CsA levels were measured ization was balanced in HTX patients. In an attempt to
in heart transplant recipients. Cardiac transplant patients balance randomization in patients with chronic nephrop-
were excluded from the study if they had a history of athy, the sequences were chosen so that placebo and
insulin-dependent or non-insulin–dependent diabetes L-Arg days were the first study days in three patients
mellitus or hypertension prior to transplantation. Char- and sodium nitroprusside (SNP) was the first day in four
acteristics of the study population are summarized in patients. In healthy volunteers, placebo and L-Arg days
Table 1. were first study days in four subjects, and SNP was the
Heart transplant recipients. The study cohort consisted first day in five subjects. To standardize the sodium bal-
of 12 male cardiac transplant recipients with impaired ance, all subjects received 3 g of sodium chloride for
kidney function and systemic hypertension, but normal three days prior to the trial days, in addition to the usual
left ventricular function. Patients had undergone heart salt intake. In addition, subjects were given a 200 ml
transplant (HTX) surgery at least eight months prior to water load one hour before the study and were stimu-
enrollment and were clinically well at the time of study. lated to drink 200 ml/hr during the renal perfusion exper-
HTX was performed as a result of dilated cardiomyopa- iments. After a 20-minute resting period in supine posi-
thy in five patients and coronary artery disease in seven tion, a primed constant infusion of paraaminohippurate
other patients. Patients were included if they had a creati- (Aminohippurate Sodium; Merck, Westpoint, PA, USA)
nine clearance between 30 and 70 ml/min. Renal function and inulin (Leavosan, Linz, Austria) was started. After
was normal before HTX (serum creatinine 1.18 6 0.09 45 minutes, a coinfusion of 17 mg/kg/min L-Arg (Clinalfa,
mg/dl). At the time of the study, patients were on triple- La¨ufelfingen, Switzerland) or 1.0 mg/kg/min SNP (Nipruss-
drug immunosuppressive regimen with CsA, azathio- Trockensubstanz; Sanol-Schwarz, Monheim, Germany)
prine, and prednisolone. All HTX patients were studied or placebo (0.9% saline, 500 ml; Leopold Pharma, Graz,
in the morning after the intake of their CsA dose. Con- Austria) was started for 30 minutes.
comitant antihypertensive treatment consisted of angio- l-arginine and SNP were diluted in 500 ml of glucose
tensin-converting enzyme inhibitors, calcium channel solution. To maintain double-blind conditions with re-
blockers, and furosemide. Because angiotensin-con- spect to the different drugs administered, infusions that
verting enzyme inhibitors and calcium-channel blockers were identical in appearance were prepared. In addition,
are likely to influence NO-dependent vasodilation, all the investigators who performed the renal perfusion ex-
patients were switched to a- and/or b-blockers three days periments were blinded regarding the underlying disease
before enrollment. of the subject under study. PAH and inulin plasma levels
Patients with chronic nephropathy. The study cohort were measured at baseline, after 15 minutes, and every
consisted of 10 male patients with chronic nephropathy. 10 minutes thereafter. The pulse rate and four-lead ECG
Patients were matched with regard to age and creatinine were monitored continuously. Blood pressure was mea-
sured in five-minute intervals. Exhaled NO concentra-clearance to the HTX study group. This group was stud-
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tion was measured at the same intervals as PAH and ratory” values from the strip-recorder readings were
used for analysis to assure that inspired NO from theinulin blood sampling.
ambient air did not distort the results. The reproducibil-
Rationale for design and doses ity and sensitivity of this method have been demon-
strated previously [18, 19].Intravenous infusion of 30 g L-Arg causes a decrease
in blood pressure, which reaches a plateau 20 minutes
Data analysisafter the start of the administration [14]. In addition, our
own experiments have demonstrated that this dose of For data description, hemodynamic parameters were
expressed as percentage changes from baseline (D%).L-Arg is well tolerated, increases RPF, and reduces renal
vascular resistance (RVR) in healthy subjects [15]. SNP The effects of L-Arg and SNP were assessed with re-
peated measure analysis of variance versus placebo. Awas used as endothelium-independent vasodilator. This
pharmacological stimulation was selected in an effort P of less than 0.05 was considered the level of significance.
For data description, values are given as means 6 sd.to investigate whether heart transplant recipients under
CsA and patients with chronic nephropathy have an al-
tered renal reactivity to exogenous NO. SNP was admin-
RESULTS
istered at a dose of 1.0 mg/kg/min, which was well toler-
Healthy subjectsated in healthy subjects and caused a small but significant
decrease in DBP [16]. l-arginine caused a significant increase in RPF (1
12%, P 5 0.009) and GFR (1 11%, P 5 0.001; Fig.
Blood pressure and pulse rate 1). By contrast, SNP did not exert any significant renal
hemodynamic effects. However, both L-Arg and SNPSystolic blood pressure, DBP, and mean arterial blood
pressure (MAP) were measured noninvasively on the significantly reduced RVR by 218% (P , 0.001) and
222% (P , 0.001), respectively. L-Arg significantly re-upper arm by an automated oscillometric device. Pulse
rate was recorded automatically using a finger pulse- duced DBP (P 5 0.030; Fig. 2) but only tended to de-
crease SBP. The effect of SNP on DBP (P , 0.001) andoximetric device (Hewlett Packard Patient monitor, Palo
Alto, CA, USA). SBP (P , 0.001) was more pronounced. L-Arg did not
affect pulse rate, whereas SNP reduced mean pulse rate
Renal hemodynamic measurements from 69 min21 to 58 min21 (P , 0.001). L-Arg, but not
SNP, significantly increased exhaled NO (Table 2).The procedure for the estimation of renal hemody-
namics using the PAH and inulin clearance technique
Heart transplant recipientswithout urine collection is described in detail elsewhere
[17]. In this study, PAH and inulin plasma concentrations Neither L-Arg nor SNP infusion affected renal hemo-
dynamics. L-Arg significantly reduced RVR (217%, P ,were determined from 6 ml of venous blood, which were
collected from intravenous cannulae into glass tubes at 0.004), whereas the effect of SNP on RVR (210%) did
not reach the level of significance. Both drugs signifi-each time point. The tubes were centrifuged at 3000 g
for 10 minutes. The clear supernatant was removed, fro- cantly reduced systemic blood pressure. Again, the effect
of SNP (SBP and DBP, P , 0.001) was more pronouncedzen, and stored at 2208C until assayed. PAH plasma
concentrations were measured by photometric analysis. than the effect of L-Arg (SBP, P 5 0.008; DBP, P ,
0.001). In contrast to the healthy control subjects, neitherInulin plasma concentrations were measured by a com-
mercially available test (Inuquant; Leavosan). RPF and L-Arg nor SNP affected the pulse rate. Again L-Arg,
but not SNP, induced a significant increase in exhaledGFR were estimated as the infusion clearance of PAH
and inulin, respectively. RVR was calculated as RVR 5 NO (Table 2).
MAP/RPF.
Patients with chronic nephropathy
Exhaled nitric oxide L-Arg did not affect renal hemodynamics. In contrast,
SNP caused a significant decrease in RPF (212%, P 5The measurement of exhaled NO was obtained using a
chemiluminescence detector (Nitrogen oxides analyzer, 0.008) and GFR (28%, P 5 0.005). Neither of the two
drugs caused a significant change in RVR in this studyModel 8840; Monitor Inc., Denver, CO, USA) [18]. Cali-
bration of the instrument was done with certified gases group. L-Arg (SBP, P 5 0.028; DBP, P 5 0.007) and
SNP (SBP and DBP, P , 0.001) significantly reduced(300 ppb NO in N2; AGA, Vienna, Austria), diluted by
precision flow meters. A baseline signal was obtained blood pressure. L-Arg did not change the pulse rate.
The effect of SNP on the pulse rate was smaller than inwith pure nitrogen. Subjects held their breath for 10
seconds and exhaled for 10 seconds into a Teflon tube healthy subjects, but a significant decrease from 84 min21
to 79 min21 was observed (P 5 0.038). Again L-Arg, butunder nasal occlusion. One thousand ml/min of exhaled
air was allowed to enter the inlet port. The “end exspi- not SNP, significantly increased exhaled NO (Table 2).
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Fig. 1. Effect of l-arginine (m), sodium nitroprusside (,), or placebo (no symbol) on renal plasma flow (RPF) and glomerular filtration rate
(GFR) in the three study cohorts. Data are presented as means 6 sd. Asterisks indicate P , 0.05 vs. predose, analysis of variance.
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Fig. 2. Effect of l-arginine (m), sodium nitroprusside (,), or placebo (no symbol) on systolic (SBP) and diastolic blood pressure (DBP) in the
three study cohorts. (A) Control subjects. (B) heart transplant patients. (C) Renal patients. Data are presented as means 6 sd. Asterisks indicate
P , 0.05 vs. predose, analysis of variance.
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Table 2. Effect of l-arginine (L-Arg), sodium nitroprusside (SNP), nal function may be seen in patients with lower
or placebo on exhaled nitric oxide (NO) levels (ppm) at the end
cyclosporine plasma levels.of the 30-minute intravenous drug infusion
There is still considerable controversy regarding the
L-Arg SNP Placebo mechanisms underlying the vasodilator effect of L-Arg.
Healthy subjects (N 5 13) Biochemical considerations indicate that L-Arg plasma
Baseline 23.166.0 21.666.8 19.167.0
concentrations are far in excess of the membrane L-Arg30 minutes 29.165.6a 23.067.2 21.565.3
HTX patients (N 5 12) transport capacity [25]. Consequently, NO synthesis may
Baseline 20.564.0 23.865.0 20.564.4 not be limited by substrate availability in healthy sub-
30 minutes 26.165.8a 21.164.4 20.563.9
jects. It has been hypothesized that L-Arg may also actChronic nephropathy patients
(N 5 10) via endothelium-independent mechanisms such as the
Baseline 27.267.9 26.467.4 28.667.9 stimulation of endogenous insulin release [26]. On the
30 minutes 32.868.4a 24.165.8 26.867.6
other hand, an increased endogenous NO production
Data are presented as means 6 sd. following L-Arg is evidenced from elevated plasma ni-a P , 0.05 vs. baseline, ANOVA
trate levels [27], increased urinary cGMP excretion [20],
and increased exhaled NO levels [27, 28], which have
also been observed in this study. Hence, we consider it
DISCUSSION likely that the hemodynamic effects of L-Arg in this
study can at least be partially attributed to the stimula-The main purpose of this study was to investigate
whether L-Arg, the precursor of NO synthesis, increases tion of endogenous NO synthesis.
In addition, we studied the effect of an endothelium-RPF in stable HTX patients on CsA therapy. L-Arg
infusion exerted a systemic hypotensive response and independent vasodilator, SNP, that acts through direct
release of NO. As expected, SNP caused a significantincreased exhaled NO to a comparable degree in all
cohorts under study. However, the effects on the renal decrease of SBP and DBP in all groups as compared
with baseline. In heart transplant recipients, the exoge-vasculature were different in the three study groups.
Whereas we observed a significant increase of RPF and nous NO donor did not change GFR or RPF, whereas
in patients with chronic nephropathy, a significant de-GFR, as well as a significant decrease in RVR in healthy
controls, L-Arg had no effect on renal hemodynamics in crease in RPF and GFR was observed during SNP ad-
ministration. Our results in healthy subjects are in keep-HTX patients and in patients with chronic nephropathy.
Previous human studies have demonstrated that L-Arg ing with previous human studies, which showed no effect
of SNP on renal blood flow [29, 30]. Two mechanismsincreases RPF by 12 to 15% in healthy subjects [14, 20]
but not in untreated hypertensive subjects [14, 21]. In could contribute to the abnormal SNP response in the
patients with chronic nephropathy. First, SNP inducedrenal transplant recipients who were free of CsA, L-Arg
induced an increase in RPF and GFR, whereas in trans- a reduction in systemic blood pressure and consequently
in renal perfusion pressure. Hence, a deficient renal auto-plant recipients who were treated with CsA, no effect
of L-Arg was observed [22]. Conversely, Andres et al regulation may account for this observation in patients
with chronic nephropathy. Second, it is also possiblefound a significant increase in RPF and GFR after L-Arg
infusion in renal transplant recipients receiving CsA [23]. that the local vasodilator response to exogenous NO is
altered in this study cohort. However, in heart transplantComparing these results with our findings, the different
experimental conditions have to be considered [22, 23]. recipients under CsA treatment, we did not observe an
abnormal SNP response in the kidney. The change inCsA plasma levels were slightly lower in the study of
Gaston et al, but the selected dose of L-Arg (30 g) was RVR during SNP administration was 28% and 217%
in healthy subjects and HTX patients, respectively.comparable to our trial [22]. Interestingly, the antagonis-
tic effect that Andres et al described was observed with Hence, our data do not indicate an altered renal reactiv-
ity to exogenous NO or abnormal renal autoregulationmuch lower doses of L-Arg (4 g), despite higher basal
CsA plasma levels [23]. Both previous human trials on in HTX patients. Rather, our data suggest that an altered
L-Arg/NO pathway after prolonged CsA treatment ex-the renal hemodynamic effect of L-Arg were performed
in renal transplant recipients under CsA treatment. It ists, but the exact mechanism remains to be elucidated.
This study also indicates that in patients with long-has, however, been previously shown that the renal func-
tional reserve is higher in heart transplant recipients than term CsA treatment, L-Arg cannot counteract the CsA-
induced reduction in RPF and GFR. Whether the acutein kidney transplant recipients [24]. This may be related
to the usually lower CsA doses in heart transplant recipi- vasoconstrictor effect of CsA can be counteracted by
L-Arg in humans cannot be answered from this study.ents as compared with kidney transplant recipients. Our
study indicates that the high doses required in HTX This may also explain, at least in part, the discrepancies
between previous rat studies [10, 12] and the presentpatients seem to prevent the clinical use of L-Arg. We
cannot exclude that antagonistic effects of L-Arg on re- experiments. Whereas animals were fed with CsA for
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of endothelial toxicity of cyclosporine A. Circ Res 74:477–484,approximately 10 days, the heart transplant recipients in
1994
our cohort were on CsA therapy for more than eight 12. Assis SMA, Monteiro JL, Segur AC: L-arginine and allopurinol
protect against cyclosporine nephrotoxicity. Transplantation 63:months. It could therefore be that the onset of treatment
1070–1073, 1997with L-Arg prior to the introduction of CsA may be
13. Bobadilla NA, Tapia E, Franco M, Lopez P, Mendoza S, Garcia-
more beneficial in HTX patients. Torres R, Alvarado JA, Herrera-Acosta J: Role of nitric oxide
in renal hemodynamic abnormalities of cyclosporine nephrotoxic-In conclusion, our results indicate that the renal hemo-
ity. Kidney Int 46:773–779, 1994dynamic response to L-Arg is different in heart trans-
14. Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H,
plant recipients under chronic CsA compared with healthy Kajiyama G: Effects of L-arginine infusion on renal hemodynamics
in patients with mild essential hypertension. Hypertension 25:898–subjects. By contrast, no evidence for an altered renal
902, 1995reactivity to exogenous NO was apparent in HTX pa-
15. Wolzt M, Ugurluoglu A, Schmetterer L, Krejcy K, Zanaschka
tients. This supports the hypothesis of an altered L-Arg/ G, Mensik C, Eichler HG: Effect of L-arginine on angiotensin II-
induced renal vasoconstriction in healthy men. Br J Clin PharmacolNO pathway in patients under long-term CsA treatment.
45:71–75, 1998
16. Wolzt M, Schmetterer L, Rheinberger A, Salomom A, Unfried
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